FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 317:1237-1245 November 12, 1987 Number 20 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter] in two consecutive pretreatment measurements). One group (2051 men) received 600 mg of gemfibrozil twice daily, and the other (2030 men) received placebo. Gemfibrozil caused a marked increase in HDL cholesterol and persistent reductions in serum levels of total, low-density lipoprotein (LDL), and non-HDL cholesterol and triglycerides. There were minimal changes in serum lipid levels in the placebo group. The cumulative rate of cardiac end points at five years was 27.3 per 1,000 in the gemfibrozil group and 41.4 per 1,000 in the placebo group--a reduction of 34.0 percent in the incidence of coronary heart disease (95 percent confidence interval, 8.2 to 52.6; P less than 0.02; two-tailed test). The decline in incidence in the gemfibrozil group became evident in the second year and continued throughout the study. There was no difference between the groups in the total death rate, nor did the treatment influence the cancer rates. The results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.

Source Information

First Department of Medicine, University of Helsinki, Finland.

This article has been cited by other articles:

• Chapman, M. J., Le Goff, W., Guerin, M., Kontush, A. (2009). Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 0: ehp399v1-ehp399 [Abstract] [Full Text]  
• Whayne, T. F. Jr (2009). High-density Lipoprotein Cholesterol: Current Perspective for Clinicians. ANGIOLOGY 60: 644-649 [Abstract]  
• Su, Z., Ishimori, N., Chen, Y., Leiter, E. H., Churchill, G. A., Paigen, B., Stylianou, I. M. (2009). Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene. J. Lipid Res. 50: 2083-2094 [Abstract] [Full Text]  
• Miller, M. (2009). Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102: 657-667 [Abstract] [Full Text]  
• Ford, E. S., Li, C., Zhao, G., Pearson, W. S., Mokdad, A. H. (2009). Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults. Arch Intern Med 169: 572-578 [Abstract] [Full Text]  
• Goldenberg, I., Boyko, V., Tennenbaum, A., Tanne, D., Behar, S., Guetta, V. (2009). Long-term Benefit of High-Density Lipoprotein Cholesterol-Raising Therapy With Bezafibrate: 16-Year Mortality Follow-up of the Bezafibrate Infarction Prevention Trial. Arch Intern Med 169: 508-514 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., Nissen, S. E. (2008). Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514 [Abstract] [Full Text]  
• Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H. (2008). The Metabolic Syndrome. Endocr. Rev. 29: 777-822 [Abstract] [Full Text]  
• Farnier, M., Perevozskaya, I., Taggart, W. V., Kush, D., Mitchel, Y. B. (2008). VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J. Lipid Res. 49: 2641-2647 [Abstract] [Full Text]  
• Mukherjee, R., Locke, K. T., Miao, B., Meyers, D., Monshizadegan, H., Zhang, R., Search, D., Grimm, D., Flynn, M., O'Malley, K. M., Zhang, L., Li, J., Shi, Y., Kennedy, L. J., Blanar, M., Cheng, P. T., Tino, J., Srivastava, R. A. (2008). Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist. J. Pharmacol. Exp. Ther. 327: 716-726 [Abstract] [Full Text]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• Ferns, G, Keti, V, Griffin, B (2008). Investigation and management of hypertriglyceridaemia. J. Clin. Pathol. 61: 1174-1183 [Abstract] [Full Text]  
• Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., DeFilippis, A. P. (2008). A Practical 'ABCDE' Approach to the Metabolic Syndrome. Mayo Clin Proc. 83: 932-943 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B. (2008). Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men. Arterioscler. Thromb. Vasc. Bio. 28: 1050-1059 [Abstract] [Full Text]  
• Kuipers, I., van der Harst, P., Navis, G., van Genne, L., Morello, F., van Gilst, W. H., van Veldhuisen, D. J., de Boer, R. A. (2008). Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System. Hypertension 51: 1442-1448 [Full Text]  
• Ruan, X., Zheng, F., Guan, Y. (2008). PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal Physiol. 294: F1032-F1047 [Abstract] [Full Text]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512-1524 [Full Text]  
• Kourimate, S., Le May, C., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zair, Y., Nguyen, P., Krempf, M., Cariou, B., Costet, P. (2008). Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9. J. Biol. Chem. 283: 9666-9673 [Abstract] [Full Text]  
• Fowler, M. J. (2008). Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes 26: 77-82 [Full Text]  
• Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811-822 [Full Text]  
• Kumar, V., Khan, M. M., Khanna, A. K., Singh, R., Singh, S., Chander, R., Mahdi, F., Mahdi, A. A., Saxena, J. K., Singh, R. K. (2008). Lipid Lowering Activity of Anthocephalus indicus Root in Hyperlipidemic Rats. Evid Based Complement Alternat Med 0: nen001v1-nen001 [Abstract] [Full Text]  
• Stirban, A. O., Tschoepe, D. (2008). Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care 31: S226-S228 [Abstract] [Full Text]  
• Goldenberg, I., Benderly, M., Goldbourt, U., for the BIP Study Group, (2008). Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.. J Am Coll Cardiol 51: 459-465 [Abstract] [Full Text]  
• deGoma, E. M., Leeper, N. J., Heidenreich, P. A. (2008). Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.. J Am Coll Cardiol 51: 49-55 [Abstract] [Full Text]  
• Lavie, C. J., Milani, R. V. (2008). Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.. J Am Coll Cardiol 51: 56-58 [Full Text]  
• Poppius, E, Virkkunen, H, Hakama, M, Tenkanen, L (2008). The sense of coherence and risk of injuries: role of alcohol consumption and occupation. J. Epidemiol. Community Health 62: 35-41 [Abstract] [Full Text]  
• Barter, P. J., Rye, K.-A. (2008). Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?. Arterioscler. Thromb. Vasc. Bio. 28: 39-46 [Abstract] [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• Steiner, G. (2007). Atherosclerosis in type 2 diabetes: a role for fibrate therapy?. Diabetes and Vascular Disease Research 4: 368-374 [Abstract]  
• Valasek, M. A., Clarke, S. L., Repa, J. J. (2007). Fenofibrate reduces intestinal cholesterol absorption via PPAR{alpha}-dependent modulation of NPC1L1 expression in mouse. J. Lipid Res. 48: 2725-2735 [Abstract] [Full Text]  
• Babaev, V. R., Ishiguro, H., Ding, L., Yancey, P. G., Dove, D. E., Kovacs, W. J., Semenkovich, C. F., Fazio, S., Linton, M. F. (2007). Macrophage Expression of Peroxisome Proliferator Activated Receptor-{alpha} Reduces Atherosclerosis in Low-Density Lipoprotein Receptor Deficient Mice. Circulation 116: 1404-1412 [Abstract] [Full Text]  
• Brunzell, J. D. (2007). Hypertriglyceridemia. NEJM 357: 1009-1017 [Full Text]  
• Zambon, A., Cusi, K. (2007). The role of fenofibrate in clinical practice. Diabetes and Vascular Disease Research 4: S15-S20 [Abstract]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• Nogueira, J., Weir, M. (2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN 2: 766-785 [Abstract] [Full Text]  
• Hegele, R. A., Pollex, R. L. (2007). Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates. Arterioscler. Thromb. Vasc. Bio. 27: 1224-1227 [Full Text]  
• Zambon, A. (2007). Type 2 diabetes patients: profiles, treatment and daily practice. Diabetes and Vascular Disease Research 4: S12-S16  
• Yuan, G., Al-Shali, K. Z., Hegele, R. A. (2007). Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176: 1113-1120 [Abstract] [Full Text]  
• Nissen, S. E., Nicholls, S. J., Wolski, K., Howey, D. C., McErlean, E., Wang, M.-D., Gomez, E. V., Russo, J. M. (2007). Effects of a Potent and Selective PPAR-{alpha} Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia: Two Randomized Controlled Trials. JAMA 297: 1362-1373 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., Kapadia, S. R., Nissen, S. E. (2007). Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA 297: 499-508 [Abstract] [Full Text]  
• Tuohimaa, P., Tenkanen, L., Syvala, H., Lumme, S., Hakulinen, T., Dillner, J., Hakama, M. (2007). Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev. 16: 302-307 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2007). Prevention of Cardiovascular Disease. Diabetes Care 30: 423-431 [Abstract] [Full Text]  
• Brown, J. D., Plutzky, J. (2007). Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets. Circulation 115: 518-533 [Abstract] [Full Text]  
• Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., Pignone, M. P., Plutzky, J., Porte, D., Redberg, R., Stitzel, K. F., Stone, N. J. (2007). Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation 115: 114-126 [Abstract] [Full Text]  
• Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., Pignone, M. P., Plutzky, J., Porte, D., Redberg, R., Stitzel, K. F., Stone, N. J. (2007). Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30: 162-172 [Abstract] [Full Text]  
• American Diabetes Association, (2007). Standards of Medical Care in Diabetes--2007. Diabetes Care 30: S4-S41 [Full Text]  
• Akoglu, H., Yilmaz, R., Kirkpantur, A., Arici, M., Altun, B., Turgan, C. (2007). Combined Organ Failure with Combination Antihyperlipidemic Treatment: A Case of Hepatic Injury and Acute Renal Failure. The Annals of Pharmacotherapy 41: 143-147 [Abstract] [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation 114: 2850-2870 [Full Text]  
• Wierzbicki, A. S (2006). Fibrates after the FIELD study: some answers, more questions. Diabetes and Vascular Disease Research 3: 166-171 [Abstract]  
• Menard, J., Ardilouze, J.-L. (2006). Multitherapy for diabetes. CMAJ 175: 1247-1247 [Full Text]  
• Freeman, S. R., Drake, A. L., Heilig, L. F., Graber, M., McNealy, K., Schilling, L. M., Dellavalle, R. P. (2006). Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis.. JNCI J Natl Cancer Inst 98: 1538-1546 [Abstract] [Full Text]  
• Zadelaar, A. S. M., Boesten, L. S.M., Jukema, J. W., van Vlijmen, B. J.M., Kooistra, T., Emeis, J. J., Lundholm, E., Camejo, G., Havekes, L. M. (2006). Dual PPAR{alpha}/{gamma} Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice. Arterioscler. Thromb. Vasc. Bio. 26: 2560-2566 [Abstract] [Full Text]  
• Gilde, A. J., Fruchart, J.-C., Staels, B. (2006). Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. J Am Coll Cardiol 48: A24-A32 [Abstract] [Full Text]  
• Steinmetz, A. (2006). Lipid-lowering therapy in type 2 diabetes: a review of the evidence. Diabetes and Vascular Disease Research 3: S10-S15 [Abstract]  
• Graham, R. A., Goodwin, B., Merrihew, R. V., Krol, W. L., LeCluyse, E. L. (2006). Cloning, Tissue Expression, and Regulation of Beagle Dog CYP4A Genes. Toxicol Sci 92: 356-367 [Abstract] [Full Text]  
• Mittleman, M. A. (2006). A 39-year-old woman with hypercholesterolemia.. JAMA 296: 319-326 [Abstract] [Full Text]  
• McQueen, M. (2006). Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes. Evid. Based Med. 11: 86-86 [Full Text]  
• Virkkunen, H, Harma, M, Kauppinen, T, Tenkanen, L (2006). The triad of shift work, occupational noise, and physical workload and risk of coronary heart disease.. Occup. Environ. Med. 63: 378-386 [Abstract] [Full Text]  
• Costa, J., Borges, M., David, C., Vaz Carneiro, A. (2006). Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332: 1115-1124 [Abstract] [Full Text]  
• Najman, D. M. (2006). Adverse events related to muraglitazar use in diabetes.. JAMA 295: 1997-1997 [Full Text]  
• Zambon, A., Gervois, P., Pauletto, P., Fruchart, J.-C., Staels, B. (2006). Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence. Arterioscler. Thromb. Vasc. Bio. 26: 977-986 [Abstract] [Full Text]  
• Bloomfield, H. E. (2006). The role of fibrates in a statin world.. Arch Intern Med 166: 715-716 [Full Text]  
• Tenkanen, L., Manttari, M., Kovanen, P. T., Virkkunen, H., Manninen, V. (2006). Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study.. Arch Intern Med 166: 743-748 [Abstract] [Full Text]  
• Olson, K. L., Potts, L. A. (2006). Role of the Pharmacist in the Management of Dyslipidemia. Journal of Pharmacy Practice 19: 94-102 [Abstract]  
• Kanbay, M., Yildirir, A., Ulus, T., Bilgi, M., Kucuk, A., Muderrisoglu, H. (2006). Rhesus Positivity and Low High-Density Lipoprotein Cholesterol: A New Link?. Asian Cardiovasc. Thorac. Ann. 14: 119-122 [Abstract] [Full Text]  
• Barter, P. J., Rye, K.-A. (2006). Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?. Circulation 113: 1553-1555 [Full Text]  
• Resnick, H. E., Foster, G. L., Bardsley, J., Ratner, R. E. (2006). Achievement of american diabetes association clinical practice recommendations among u.s. Adults with diabetes, 1999-2002: the national health and nutrition examination survey.. Diabetes Care 29: 531-537 [Abstract] [Full Text]  
• Chapman, M J. (2006). Review: Fibrates: therapeutic review. British Journal of Diabetes & Vascular Disease 6: 11-19 [Abstract]  
• Steinberg, D. (2006). Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it--almost. J. Lipid Res. 47: 1-14 [Abstract] [Full Text]  
• American Diabetes Association, (2006). Standards of Medical Care in Diabetes-2006. Diabetes Care 29: S4-S42 [Full Text]  
• Ohashi, R., Mu, H., Wang, X., Yao, Q., Chen, C. (2005). Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 98: 845-856 [Abstract] [Full Text]  
• Prepared by: British Cardiac Society, British Hype, (2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91: v1-v52 [Full Text]  
• Nissen, S. E., Wolski, K., Topol, E. J. (2005). Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA 294: 2581-2586 [Abstract] [Full Text]  
• Young, I. S. (2005). Lipids for Psychiatrists - an overview. J Psychopharmacol 19: 66-75 [Abstract]  
• Nicholls, S. J., Cutri, B., Worthley, S. G., Kee, P., Rye, K.-A., Bao, S., Barter, P. J. (2005). Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits. Arterioscler. Thromb. Vasc. Bio. 25: 2416-2421 [Abstract] [Full Text]  
• Libby, P. (2005). The Forgotten Majority: Unfinished Business in Cardiovascular Risk Reduction. J Am Coll Cardiol 46: 1225-1228 [Abstract] [Full Text]  
• Gotto, A. M. Jr (2005). Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture. J Am Coll Cardiol 46: 1219-1224 [Full Text]  
• Ashen, M. D., Blumenthal, R. S. (2005). Low HDL Cholesterol Levels. NEJM 353: 1252-1260 [Full Text]  
• Colman, E. (2005). Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants. ANN INTERN MED 143: 380-385 [Abstract] [Full Text]  
• Eddy, D. M., Schlessinger, L., Kahn, R. (2005). Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. ANN INTERN MED 143: 251-264 [Abstract] [Full Text]  
• Ong, H.T. (2005). The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98: 599-614 [Abstract] [Full Text]  
• Staels, B., Fruchart, J.-C. (2005). Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists. Diabetes 54: 2460-2470 [Abstract] [Full Text]  
• Assmann, G. (2005). Calculating global risk: the key to intervention. Eur Heart J Suppl 7: F9-F14 [Abstract] [Full Text]  
• Shepherd, J. (2005). Raising HDL-cholesterol and lowering CHD risk: does intervention work?. Eur Heart J Suppl 7: F15-F22 [Abstract] [Full Text]  
• Kastelein, J. J.P. (2005). The realities of dyslipidaemia: what do the studies tell us?. Eur Heart J Suppl 7: F27-F33 [Abstract] [Full Text]  
• Brown, B. G. (2005). Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 7: F34-F40 [Abstract] [Full Text]  
• Chapman, J. (2005). Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J Suppl 7: F56-F62 [Abstract] [Full Text]